NeuroSense Therapeutics (NRSN) Corporate presentation summary

Clinical development and pipeline

• Lead asset PrimeC is Phase 3-ready for ALS, with initiation expected mid-2026 and a robust pipeline targeting ALS, Alzheimer's, and Parkinson's diseases.

• PrimeC has orphan drug designation and utilizes the expedited 505(b)(2) regulatory pathway.

PrimeC clinical results and efficacy

• Phase 2b PARADIGM study showed PrimeC slowed ALS progression by 32.8% over 18 months (p=0.007) and improved survival by 65% (median survival difference ~15 months, p=0.02).

• PrimeC demonstrated a favorable safety and tolerability profile, with most adverse events mild or moderate and only two transient serious events.

• Early and continuous treatment with PrimeC led to better clinical outcomes, including significant improvements in bulbar and respiratory function.

Mechanism of action and biomarker engagement

• PrimeC is a patented, fixed-dose combination of two approved drugs with synchronized release, targeting neuroinflammation, iron metabolism, and miRNA dysregulation.

• Demonstrated significant modulation of ALS-linked miRNAs and iron metabolism biomarkers, correlating with clinical benefit.